<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 5 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Georgia;
panose-1:2 4 5 2 5 4 5 2 3 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Calibri",sans-serif;
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Calibri",sans-serif;
font-weight:bold;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style></head><body lang=EN-CA link=blue vlink="#954F72" style='word-wrap:break-word'><div class=WordSection1><p class=MsoNormal><span lang=EN-US>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US>See below for an interesting article wrt ADT.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US>Take care & stay well.</span></p><p class=MsoNormal>Glen</p><p class=MsoNormal>Sent from <a href="https://go.microsoft.com/fwlink/?LinkId=550986">Mail</a> for Windows</p><p class=MsoNormal><o:p> </o:p></p><div style='mso-element:para-border-div;border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal style='border:none;padding:0cm'><b>From: </b><a href="mailto:noreply+feedproxy@google.com">THE "NEW" PROSTATE CANCER INFOLINK</a><br><b>Sent: </b>August 12, 2021 9:06 PM<br><b>To: </b><a href="mailto:glen46nor@gmail.com">glen46nor@gmail.com</a><br><b>Subject: </b>The Prostate Cancer InfoLink</p></div><p class=MsoNormal><o:p> </o:p></p><div style='margin-left:24.0pt;margin-right:24.0pt' id=emailbody><table class=MsoNormalTable border=0 cellpadding=0 width="100%" style='width:100.0%'><tr><td width="99%" valign=top style='width:99.0%;padding:0cm 0cm 0cm 0cm'><h1 style='margin:0cm'><a href="https://prostatecancerinfolink.net" title="(https://prostatecancerinfolink.net)"><span style='font-size:16.5pt;font-family:"Arial",sans-serif;color:#888888;font-weight:normal'>The Prostate Cancer InfoLink</span></a> <o:p></o:p></h1></td><td width="1%" style='width:1.0%;padding:0cm 0cm 0cm 0cm'></td></tr></table><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia",serif;color:black'><img border=0 width=644 height=1 style='width:6.7083in;height:.0104in' id="Horizontal_x0020_Line_x0020_1" src="cid:image002.png@01D79034.9263C470"></span><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia",serif;color:black'><o:p></o:p></span></p><table class=MsoNormalTable border=0 cellpadding=0 id=itemcontentlist><tr><td style='padding:.75pt .75pt .75pt .75pt'><p style='mso-margin-top-alt:12.0pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:16.8pt'><a name=1></a><a href="http://feedproxy.google.com/~r/TheProstateCancerInfolink/~3/YEpHNQGoetA/?utm_source=feedburner&utm_medium=email"><span style='mso-bookmark:1'><b><span style='font-size:13.5pt;font-family:"Arial",sans-serif;color:#000099;text-decoration:none'>Timing of initiation of ADT for men with biochemical progression after first-line surgery</span></b></span><span style='mso-bookmark:1'></span></a> </p><p style='mso-margin-top-alt:6.75pt;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia",serif;color:#555555'>Posted: 12 Aug 2021 11:56 AM PDT<o:p></o:p></span></p><div><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia",serif;color:black'>For many years your sitemaster has been advising patients that overly early use of androgen deprivation therapy (ADT) in many men with progressive prostate cancer is not necessarily the best decision (for a number of possible reasons). The benefits of such early ADT — in terms of metastasis-free survival (MFS) and/or overall survival (OS) — […]<o:p></o:p></span></p></div></td></tr></table><p class=MsoNormal style='line-height:140%'><span style='font-size:10.0pt;line-height:140%;font-family:"Georgia",serif;color:black;display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=1 cellpadding=0 width="100%" style='width:100.0%;border:none;border-top:solid #999999 1.0pt' id=footer><tr><td style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm'><span style='font-size:8.5pt;font-family:"Helvetica",sans-serif;color:#333333'>You are subscribed to email updates from <a href="https://prostatecancerinfolink.net">THE "NEW" PROSTATE CANCER INFOLINK</a>.<br><br><o:p></o:p></span></p></td><td valign=top style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal align=right style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm;text-align:right'><span style='font-size:8.5pt;font-family:"Helvetica",sans-serif;color:#333333'>Email delivery powered by Google<o:p></o:p></span></p></td></tr><tr><td colspan=2 style='border:none;padding:3.0pt .75pt .75pt .75pt'><p class=MsoNormal style='mso-margin-top-alt:0cm;margin-right:4.5pt;margin-bottom:14.4pt;margin-left:0cm'><span style='font-size:8.5pt;font-family:"Helvetica",sans-serif;color:#333333'>Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States<o:p></o:p></span></p></td></tr></table></div><p class=MsoNormal style='mso-margin-top-alt:0cm;margin-right:24.0pt;margin-bottom:0cm;margin-left:24.0pt;margin-bottom:.0001pt'><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p></div></body></html>